{"id":"folfox-or-capox-adjuvant-chemotherapy","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neuropathy (peripheral sensory)"},{"rate":"30-40","effect":"Nausea and vomiting"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"20-30","effect":"Neutropenia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"10-20","effect":"Anemia"},{"rate":"5-10","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL4650400","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FOLFOX combines 5-fluorouracil (5-FU), leucovorin, and oxaliplatin; CAPOX substitutes capecitabine for infusional 5-FU. Oxaliplatin is a platinum agent that forms DNA crosslinks, while fluoropyrimidines inhibit thymidylate synthase and incorporate into DNA/RNA. Together they create synergistic cytotoxic effects against rapidly dividing cancer cells.","oneSentence":"FOLFOX and CAPOX are combination chemotherapy regimens that use fluorouracil and oxaliplatin to damage cancer cell DNA and inhibit cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:11.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of stage III colon cancer"},{"name":"Adjuvant treatment of stage II colon cancer (high-risk features)"}]},"trialDetails":[{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT06107920","phase":"PHASE3","title":"Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-05-07","conditions":"Colon Cancer","enrollment":232},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT07340567","phase":"PHASE3","title":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-01","conditions":"Colorectal Cancer","enrollment":2450},{"nctId":"NCT07188025","phase":"PHASE3","title":"ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2025-10","conditions":"Rectal Cancer","enrollment":103},{"nctId":"NCT05775146","phase":"PHASE2","title":"SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2024-06-18","conditions":"Colorectal Cancer, Liver Metastasis Colon Cancer","enrollment":24},{"nctId":"NCT06475352","phase":"PHASE2","title":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-01-20","conditions":"Digestive Cancer, Colorectal Cancer","enrollment":400},{"nctId":"NCT05534087","phase":"PHASE3","title":"Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2022-12-15","conditions":"Colon Cancer","enrollment":236},{"nctId":"NCT04679597","phase":"","title":"Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2016-01-01","conditions":"Rectal Cancer","enrollment":161},{"nctId":"NCT05496491","phase":"NA","title":"Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Larissa University Hospital","startDate":"2022-08-30","conditions":"Rectal Neoplasms","enrollment":84},{"nctId":"NCT04488159","phase":"PHASE3","title":"Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer","status":"WITHDRAWN","sponsor":"Johannes Laengle, MD, PhD","startDate":"2024-12-01","conditions":"Colon Cancer Stage III","enrollment":""},{"nctId":"NCT00958737","phase":"PHASE3","title":"Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer","status":"UNKNOWN","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2009-05-12","conditions":"Colorectal Cancer","enrollment":2000},{"nctId":"NCT02974556","phase":"PHASE3","title":"Proactive Management of Endoperitoneal Spread in Colonic Cancer","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2024-03-01","conditions":"Colon Cancer, Intraperitoneal Rectal Cancer","enrollment":140},{"nctId":"NCT01558921","phase":"PHASE3","title":"Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2011-06-21","conditions":"Rectal Cancer","enrollment":920},{"nctId":"NCT05274945","phase":"PHASE2","title":"Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2020-01-01","conditions":"Rectal Cancer","enrollment":58},{"nctId":"NCT03748680","phase":"PHASE2","title":"IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer","status":"UNKNOWN","sponsor":"Karen-Lise Garm Spindler","startDate":"2018-10-01","conditions":"Colorectal Cancer, Circulating Tumor DNA, Adjuvant Chemotherapy","enrollment":64},{"nctId":"NCT05194878","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-12-01","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":840},{"nctId":"NCT02231086","phase":"PHASE3","title":"Adjuvant HIPEC in High Risk Colon Cancer","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2015-03","conditions":"Colorectal Neoplasms, Peritoneal Neoplasms","enrollment":204},{"nctId":"NCT01880658","phase":"PHASE2","title":"Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2013-06","conditions":"Colorectal Neoplasms","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4361,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FOLFOX or CAPOX adjuvant chemotherapy","genericName":"FOLFOX or CAPOX adjuvant chemotherapy","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FOLFOX and CAPOX are combination chemotherapy regimens that use fluorouracil and oxaliplatin to damage cancer cell DNA and inhibit cell division. Used for Adjuvant treatment of stage III colon cancer, Adjuvant treatment of stage II colon cancer (high-risk features).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}